RT GLP3

RT GLP3 is the first triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously to deliver superior weight loss and metabolic improvement exceeding any single or dual-agonist therapy—achieving 24.2% weight loss (approximately 50+ pounds) in individuals with obesity over 48 weeks and 16.9% in those with type 2 diabetes, with hepatic steatosis resolution in 85% of participants.

The triple mechanism works synergistically: GLP-1 suppresses appetite and improves glucose sensitivity, GIP enhances insulin secretion and reduces triglycerides, and glucagon boosts metabolic rate and fat burning, combining effects into comprehensive metabolic optimization impossible with dual therapy alone. Studies show dramatic reductions in liver fat (55-65%), visceral fat, triglycerides (40%+), and inflammatory markers alongside improved cardiac and metabolic parameters. Superior efficacy at lower doses versus semaglutide or tirzepatide positions it as next-generation metabolic treatment. For individuals with obesity, metabolic syndrome, fatty liver disease, or type 2 diabetes, Retatrutide represents a pharmaceutical breakthrough delivering transformative metabolic improvement and genuine lifespan extension potential